<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are associated with a clustering of interrelated plasma <z:chebi fb="23" ids="18059">lipid</z:chebi> and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> abnormalities, which include reduced <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, a predominance of small dense <z:chebi fb="15" ids="39026">LDL</z:chebi> particles, and <z:mp ids='MP_0005317'>elevated triglyceride levels</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Each of these dyslipidemic features is associated with an increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Increased hepatic secretion of large <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-rich <z:chebi fb="1" ids="39027">VLDL</z:chebi> and impaired clearance of <z:chebi fb="1" ids="39027">VLDL</z:chebi> appears to be of central importance in the pathophysiology of this <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Small dense <z:chebi fb="15" ids="39026">LDL</z:chebi> particles arise from the intravascular processing of specific larger <z:chebi fb="1" ids="39027">VLDL</z:chebi> precursors </plain></SENT>
<SENT sid="4" pm="."><plain>Typically, reduced plasma <z:chebi fb="17" ids="39025">HDL</z:chebi> levels in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are manifest as reductions in the <z:chebi fb="17" ids="39025">HDL</z:chebi>(2b) subspecies and relative or absolute increases in smaller denser <z:chebi fb="17" ids="39025">HDL</z:chebi>(3b) and <z:chebi fb="17" ids="39025">HDL</z:chebi>(3c) </plain></SENT>
<SENT sid="5" pm="."><plain>Although behavioral interventions such as diet and exercise can improve diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, for most patients, pharmacological therapy is needed to reach treatment goals </plain></SENT>
<SENT sid="6" pm="."><plain>There are several classes of medications that can be used to treat <z:chebi fb="23" ids="18059">lipid</z:chebi> and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> abnormalities associated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, including <z:chebi fb="0" ids="35664">statins</z:chebi>, fibrates, niacin, and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Clinical trials have shown significant improvement in <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> after diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> treatment </plain></SENT>
</text></document>